Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTCs stronger for Taisho in first quarter

This article was originally published in Scrip

Executive Summary

Taisho saw its mainstay over-the-counter products rebound in the first quarter to June 30th, when net sales from self-medication operations rose by 11% to ¥38.6 billion ($358.9 million). Prescription sales were 4% higher at ¥23.2 billion, but were held back by a 7% year-on-year fall for top product Clarith (clarithromycin) to ¥5.7 billion following the general reimbursement price cut in April. Group net profit for the quarter was 28% higher at ¥7.7 billion, boosting earnings per share by the same margin to ¥25.87. Helped by cost cutting, the operating figure jumped by 42% to ¥11.6 billion.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts